Scorpiniti to take top spot at Katz Group
MISSISSAUGA, Ontario — The retirement of Katz Group Canada CEO Andy Giancamilli come February will mark the rise of pharmacy veteran Frank Scorpiniti, who will take the helm of the Canadian retailer.
Scorpiniti joined Katz Group Canada in April 2011 as COO. Long regarded as one of the bright young executives in retail pharmacy, Scorpiniti now will get a chance to lead a progressive Canadian pharmacy chain, with a hot new Rexall Healthy Living concept, a national presence under Rexall and a slew of innovative programs like the employer-based Rexall Network program.
“We brought Frank on board in April of this year, and he’ll take over Feb. 1, which is almost a year transition. We got to know him and feel very comfortable with his leadership style. So we are leaving the company in good hands, and it is a strong company,” Giancamilli told Drug Store News. “You know when it’s the right time, and it’s the right time.”
With more than 20 years of retail pharmacy experience, Scorpiniti previously served as SVP pharmacy operations at Duane Reade, a post he held since December 2008. At Duane Reade, the efforts on the back end in pharmacy, spearheaded by Scorpiniti and his team, resulted in a cost reduction for the company, better in-stocks for stores and less wait time for pharmacy customers.
Scorpiniti came to Duane Reade from West Coast regional player Longs Drug Stores, which was acquired by CVS Caremark in October 2008. While at Longs, Scorpiniti held positions of increasing responsibility and ultimately served as VP pharmacy operations, overseeing all aspects of Longs’ pharmacy business.
Now Scorpiniti inherits Katz Group, which encompasses more than 1,800 chain, franchise and independent pharmacies across Canada.
Lupin launches contraceptive authorized generic
NEW YORK — Indian generic drug maker Lupin has launched an authorized generic version of a birth control pill made by Warner Chilcott, according to published reports.
Dow Jones reported that Lupin launched an authorized generic of Femcon (norethindrone and ethinyl estradiol tablets, ferrous fumarate tablets).
An authorized generic is a branded drug sold under its generic name at a reduced price, usually through a third-party company.
NCPA: DMEPOS competitive bidding will drive indies out of diabetes business
ALEXANDRIA, Va. — The National Community Pharmacists Association on Tuesday released results from a survey of more than 800 independent community pharmacists about the negative consequences for their patients and their businesses if diabetes testing supplies under Medicare Part B are subjected to competitive bidding prices.
“The message from our survey is clear: applying competitive bidding prices for diabetes testing supplies to independent community pharmacies is financially unsustainable for these pharmacies,” stated NCPA EVP and CEO Douglas Hoey.
“Community pharmacists are indispensable to helping combat diabetes, whether it is the counseling they offer, the medications they dispense, the lifestyle modification classes they provide or the testing supplies they carry,” Hoey added. “But that dynamic will be harmed if these small business pharmacies are forced to walk away from a pricing structure that only a large warehouse can make work. Such a mass exodus of community pharmacies from Medicare Part B would diminish seniors’ access and the health complications that could ensue will only increase overall health costs.”
Survey results included:
- 81% of independents reported that their average Medicare diabetes patient visits his or her independent community pharmacy two or more times per month for counseling and/or diabetes testing supplies;
- 84% of community pharmacists surveyed said they would likely drop out of the program if forced to take reduced payments or competitively bid;
- If their patients were forced to obtain diabetes supplies by other means, 84% of pharmacists said their patients would suffer a significant impact; and
- The overwhelming majority (81%) of independent community pharmacies regularly deliver diabetes testing supplies to patients — often free of charge — with 28% making 30 or more deliveries per month. Without that home delivery and counseling from a community pharmacist, 65% of pharmacists predicted a significant impact on these patients, many of whom are homebound.
The U.S. Centers for Medicare and Medicaid Services has indicated that by 2016, providers of these supplies, which include testing strips, monitors, lancets and glucose control solutions, will either have to accept prices established under the mail-order competitive bidding process or competitively bid in order to continue participating in the Durable Medical Equipment, Orthotics, Prosthetics and Supplies program.
In July 2011, the average retail single payment amount for diabetes testing supplies was $37.67, whereas the Round 1 Competitive Bidding Program single payment amount for January 2011 was $14.62.
For the full survey, click here.